Sort
82,697 grants matching “vaccine development”
An in vitro diagnostic assay for the early and accurate detection of platelet-activating antibodies associated with Heparin-inducedThrombocytopenia
$1,154,002Curtis Jones · Retham Technologies, Inc. · R44 · FY2025 · HL
Vaccines and Therapeutics for Nipah and Hendra virus
$1,153,911Christopher Broder · Henry M. Jackson Fdn For The Adv Mil/Med · U01 · FY2008 · AI
Development of Influenza Virus-Like Particle (VLP) Vaccines
$1,153,679Jose M Galarza · Technovax, Inc. · R44 · FY2011 · AI
Optimization and preclinical development of a TB Multiple Antigen Presenting System (MAPS) vaccine
$1,153,542Richard Malley · Boston Children'S Hospital · R01 · FY2021 · AI
Induction of an Antitumor Immune Response in Patients with Melanoma
$1,153,528Patrick Hwu · University Of Tx Md Anderson Can Ctr · P50 · FY2012 · CA
CLINICAL EPIDEMIOLOGY &PATHOGENESIS OF ASYMPTOMATIC HSV
$1,153,520Fred Hutchinson Cancer Research Center · P01 · FY2000 · AI
Stress and Addiction Neuroscience Unit
$1,153,510Leandro Vendruscolo · National Institute On Drug Abuse · ZIA · FY2023 · DA
Toward a universal influenza virus vaccine based on live attenuated NS1-deleted influenza viruses
$1,153,495Adolfo Garcia-Sastre · Icahn School Of Medicine At Mount Sinai · R01 · FY2021 · AI
High-Throughput Dried Blood Spot (HT-DBS) Technologies in SARS COV-2 Serology and Vaccinology
$1,153,230Nicholas J Mantis · Wadsworth Center · U01 · FY2020 · CA
Human immune signatures of latent MTB infection, active disease and BCG vaccination
$1,153,021Bjoern Peters · La Jolla Institute For Immunology · U19 · FY2015 · AI
Immunization against filamentous bacteriophages to prevent bacterial infection
$1,152,978Patrick R Secor · University Of Montana · R01 · FY2018 · AI
A Novel Immunotherapy Targeting Cancer Stem Cells for the Treatment of Triple-Negative Breast Cancer
$1,152,921Joseph Patti · Agilvax, Inc. · R44 · FY2020 · CA
Marburg Vaccine Development
$1,152,389Nancy J Sullivan · National Institute Of Allergy And Infectious Diseases · ZIA · FY2009 · AI
Ebola Vaccine Development
$1,152,388Nancy J Sullivan · National Institute Of Allergy And Infectious Diseases · ZIA · FY2009 · AI
Pre-clinical study to fulfill FDA requirements for the completion of AV-1959 IND
$1,152,198Michael G Agadjanyan · Institute For Molecular Medicine · U01 · FY2015 · AG
Vector-Borne Diseases: Biology Of Vector Host Relationship
$1,152,156Jose Ribeiro · National Institute Of Allergy And Infectious Diseases · ZIA · FY2019 · AI
Immunology Team Contributions to the PSIIM
$1,152,148Ronald Germain · National Institute Of Allergy And Infectious Diseases · ZIA · FY2010 · AI
Antiviral therapeutics for flavivirus infections
$1,152,093Chelsea Byrd Olsen · Siga Technologies, Inc. · R01 · FY2013 · AI
Development of superior polymerases for next-generation mRNA therapeutic & vaccine manufacturing
$1,152,047Helge Zieler · Primrose Bio, Inc. · R44 · FY2020 · GM
Laboratory And Preclinical Studies Of Flaviviruses
$1,152,046Stephen Whitehead · National Institute Of Allergy And Infectious Diseases · ZIA · FY2023 · AI
Strategies for Cancer Immunotherapy Clinical Trials
$1,151,937Jeffrey Schlom · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Casual, Statistical and Mathematical Modeling with Serologic Data
$1,151,877Marc Lipsitch · Harvard School Of Public Health · U01 · FY2023 · CA
Multiscale Analysis of Immune Responses
$1,151,829Ronald Germain · National Institute Of Allergy And Infectious Diseases · ZIA · FY2010 · AI
Core B: Industrialization Core
$1,151,790Kartik Chandran · Albert Einstein College Of Medicine · U19 · FY2023 · AI
Cross-Kingdom Vaccine Targeting Healthcare-Associated Priority Pathogens
$1,151,780Ashraf S. Ibrahim · Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center · R01 · FY2023 · AI